#USA #New York #Halia Therapeutics #Ofirnoflast #Inflammasome

Halia Therapeutics Presentation at the Morgan Stanley Global Healthcare Conference

Halia Therapeutics, Inc., a pioneering clinical-stage biopharmaceutical enterprise, has recently announced its participation in the highly anticipated Morgan Stanley 24th Annual Global Healthcare Conference. This significant gathering will take place from September 14 to 16, 2026, in New York City, providing an essential platform for this innovative company to showcase its advances in biopharmaceutical development.

The company's CEO, Dr. David Bearss, is scheduled to deliver a comprehensive presentation on September 16, 2026, from 1:05 PM to 1:40 PM ET. His presentation will detail Halia's strategic vision, outline its research platform, and provide insights into their ongoing clinical initiatives. The focus of the presentation will center on Halia’s groundbreaking efforts in targeting diseases driven by inflammasome pathways, which are known to contribute significantly to various inflammatory conditions.

About Halia Therapeutics

Headquartered in Lehi, Utah, Halia Therapeutics is primarily engaged in the development of pioneering therapies that address significant unmet medical needs, particularly in hematologic diseases. The company’s research is grounded on the latest advancements in understanding the role of the NLRP3 inflammasome, which plays a pivotal role in the pathology of inflammation-driven diseases.

Halia’s flagship program, Ofirnoflast, is specifically designed for treating lower-risk Myelodysplastic Syndromes (MDS) and other hematological disorders where inflammasomes are implicated. This innovative approach could potentially redefine treatment protocols and improve patient outcomes by targeting the underlying causes of inflammation rather than just the symptoms.

Moreover, Halia's strategy encompasses a broader pipeline centered around the principles of human genetic resilience and precision medicine, which aims to tailor treatments to the individual needs of patients, thereby enhancing therapeutic efficacy. This focus highlights Halia's commitment to pushing the boundaries of current healthcare solutions and developing therapies that can significantly impact patient care.

Importance of the Conference Presentation

Presenting at such prestigious conferences not only amplifies Halia Therapeutics' visibility within the biopharmaceutical sector but also opens doors for potential collaborations and partnerships that could foster further innovation. Engaging with health investors, industry leaders, and fellow biopharmaceutical companies at the Morgan Stanley event provides Halia with the opportunity to articulate its vision and the significance of its research findings to a broader audience.

In conclusion, Halia Therapeutics stands at the forefront of biopharmaceutical innovation, especially in understanding and tackling inflammasome-driven diseases. As the date of the Morgan Stanley Global Healthcare Conference approaches, the biopharma community eagerly anticipates the insights Dr. Bearss will share regarding Halia's leading-edge therapies. For more information about Halia Therapeutics and its revolutionary approach to treatment, please visit www.haliatx.com.